whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives

Women are asking whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives.

They're hearing about a stream of lawsuits against these drugs.

Lawyers are targeting Yaz and Yasmin partly due to FDA warnings about the company not adequately disclosing risks in consumer ads.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote